Low-dose vaporized cannabis significantly improves neuropathic pain

Barth Wilsey, Thomas Marcotte, Reena Deutsch, Ben Gouaux, Staci Sakai, Haylee Donaghe

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Thirty-nine patients with central and peripheral neuropathic pain underwent a standardized procedure for inhaling medium-dose (3.53%), low-dose (1.29%), or placebo cannabis with the primary outcome being visual analog scale pain intensity. Psychoactive side effects and neuropsychological performance were also evaluated. Mixed-effects regression models demonstrated an analgesic response to vaporized cannabis. There was no significant difference between the 2 active dose groups' results (P >.7). The number needed to treat (NNT) to achieve 30% pain reduction was 3.2 for placebo versus low-dose, 2.9 for placebo versus medium-dose, and 25 for medium- versus low-dose. As these NNTs are comparable to those of traditional neuropathic pain medications, cannabis has analgesic efficacy with the low dose being as effective a pain reliever as the medium dose. Psychoactive effects were minimal and well tolerated, and neuropsychological effects were of limited duration and readily reversible within 1 to 2 hours. Vaporized cannabis, even at low doses, may present an effective option for patients with treatment-resistant neuropathic pain. Perspective: The analgesia obtained from a low dose of delta-9- tetrahydrocannabinol (1.29%) in patients, most of whom were experiencing neuropathic pain despite conventional treatments, is a clinically significant outcome. In general, the effect sizes on cognitive testing were consistent with this minimal dose. As a result, one might not anticipate a significant impact on daily functioning.

Original languageEnglish (US)
Pages (from-to)136-148
Number of pages13
JournalJournal of Pain
Volume14
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Neuralgia
Cannabis
Placebos
Analgesics
Pain
Numbers Needed To Treat
Dronabinol
Pain Measurement
Analgesia
Cross-Over Studies
Inhalation
Therapeutics

Keywords

  • analgesia
  • cannabis
  • clinical trial
  • Neuropathic pain
  • neuropsychological testing

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neurology
  • Clinical Neurology

Cite this

Wilsey, B., Marcotte, T., Deutsch, R., Gouaux, B., Sakai, S., & Donaghe, H. (2013). Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain, 14(2), 136-148. https://doi.org/10.1016/j.jpain.2012.10.009

Low-dose vaporized cannabis significantly improves neuropathic pain. / Wilsey, Barth; Marcotte, Thomas; Deutsch, Reena; Gouaux, Ben; Sakai, Staci; Donaghe, Haylee.

In: Journal of Pain, Vol. 14, No. 2, 02.2013, p. 136-148.

Research output: Contribution to journalArticle

Wilsey, B, Marcotte, T, Deutsch, R, Gouaux, B, Sakai, S & Donaghe, H 2013, 'Low-dose vaporized cannabis significantly improves neuropathic pain', Journal of Pain, vol. 14, no. 2, pp. 136-148. https://doi.org/10.1016/j.jpain.2012.10.009
Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. Journal of Pain. 2013 Feb;14(2):136-148. https://doi.org/10.1016/j.jpain.2012.10.009
Wilsey, Barth ; Marcotte, Thomas ; Deutsch, Reena ; Gouaux, Ben ; Sakai, Staci ; Donaghe, Haylee. / Low-dose vaporized cannabis significantly improves neuropathic pain. In: Journal of Pain. 2013 ; Vol. 14, No. 2. pp. 136-148.
@article{b8a6ba0ce7db4d459c8514f23eb5ed56,
title = "Low-dose vaporized cannabis significantly improves neuropathic pain",
abstract = "We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Thirty-nine patients with central and peripheral neuropathic pain underwent a standardized procedure for inhaling medium-dose (3.53{\%}), low-dose (1.29{\%}), or placebo cannabis with the primary outcome being visual analog scale pain intensity. Psychoactive side effects and neuropsychological performance were also evaluated. Mixed-effects regression models demonstrated an analgesic response to vaporized cannabis. There was no significant difference between the 2 active dose groups' results (P >.7). The number needed to treat (NNT) to achieve 30{\%} pain reduction was 3.2 for placebo versus low-dose, 2.9 for placebo versus medium-dose, and 25 for medium- versus low-dose. As these NNTs are comparable to those of traditional neuropathic pain medications, cannabis has analgesic efficacy with the low dose being as effective a pain reliever as the medium dose. Psychoactive effects were minimal and well tolerated, and neuropsychological effects were of limited duration and readily reversible within 1 to 2 hours. Vaporized cannabis, even at low doses, may present an effective option for patients with treatment-resistant neuropathic pain. Perspective: The analgesia obtained from a low dose of delta-9- tetrahydrocannabinol (1.29{\%}) in patients, most of whom were experiencing neuropathic pain despite conventional treatments, is a clinically significant outcome. In general, the effect sizes on cognitive testing were consistent with this minimal dose. As a result, one might not anticipate a significant impact on daily functioning.",
keywords = "analgesia, cannabis, clinical trial, Neuropathic pain, neuropsychological testing",
author = "Barth Wilsey and Thomas Marcotte and Reena Deutsch and Ben Gouaux and Staci Sakai and Haylee Donaghe",
year = "2013",
month = "2",
doi = "10.1016/j.jpain.2012.10.009",
language = "English (US)",
volume = "14",
pages = "136--148",
journal = "Journal of Pain",
issn = "1526-5900",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Low-dose vaporized cannabis significantly improves neuropathic pain

AU - Wilsey, Barth

AU - Marcotte, Thomas

AU - Deutsch, Reena

AU - Gouaux, Ben

AU - Sakai, Staci

AU - Donaghe, Haylee

PY - 2013/2

Y1 - 2013/2

N2 - We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Thirty-nine patients with central and peripheral neuropathic pain underwent a standardized procedure for inhaling medium-dose (3.53%), low-dose (1.29%), or placebo cannabis with the primary outcome being visual analog scale pain intensity. Psychoactive side effects and neuropsychological performance were also evaluated. Mixed-effects regression models demonstrated an analgesic response to vaporized cannabis. There was no significant difference between the 2 active dose groups' results (P >.7). The number needed to treat (NNT) to achieve 30% pain reduction was 3.2 for placebo versus low-dose, 2.9 for placebo versus medium-dose, and 25 for medium- versus low-dose. As these NNTs are comparable to those of traditional neuropathic pain medications, cannabis has analgesic efficacy with the low dose being as effective a pain reliever as the medium dose. Psychoactive effects were minimal and well tolerated, and neuropsychological effects were of limited duration and readily reversible within 1 to 2 hours. Vaporized cannabis, even at low doses, may present an effective option for patients with treatment-resistant neuropathic pain. Perspective: The analgesia obtained from a low dose of delta-9- tetrahydrocannabinol (1.29%) in patients, most of whom were experiencing neuropathic pain despite conventional treatments, is a clinically significant outcome. In general, the effect sizes on cognitive testing were consistent with this minimal dose. As a result, one might not anticipate a significant impact on daily functioning.

AB - We conducted a double-blind, placebo-controlled, crossover study evaluating the analgesic efficacy of vaporized cannabis in subjects, the majority of whom were experiencing neuropathic pain despite traditional treatment. Thirty-nine patients with central and peripheral neuropathic pain underwent a standardized procedure for inhaling medium-dose (3.53%), low-dose (1.29%), or placebo cannabis with the primary outcome being visual analog scale pain intensity. Psychoactive side effects and neuropsychological performance were also evaluated. Mixed-effects regression models demonstrated an analgesic response to vaporized cannabis. There was no significant difference between the 2 active dose groups' results (P >.7). The number needed to treat (NNT) to achieve 30% pain reduction was 3.2 for placebo versus low-dose, 2.9 for placebo versus medium-dose, and 25 for medium- versus low-dose. As these NNTs are comparable to those of traditional neuropathic pain medications, cannabis has analgesic efficacy with the low dose being as effective a pain reliever as the medium dose. Psychoactive effects were minimal and well tolerated, and neuropsychological effects were of limited duration and readily reversible within 1 to 2 hours. Vaporized cannabis, even at low doses, may present an effective option for patients with treatment-resistant neuropathic pain. Perspective: The analgesia obtained from a low dose of delta-9- tetrahydrocannabinol (1.29%) in patients, most of whom were experiencing neuropathic pain despite conventional treatments, is a clinically significant outcome. In general, the effect sizes on cognitive testing were consistent with this minimal dose. As a result, one might not anticipate a significant impact on daily functioning.

KW - analgesia

KW - cannabis

KW - clinical trial

KW - Neuropathic pain

KW - neuropsychological testing

UR - http://www.scopus.com/inward/record.url?scp=84873287705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873287705&partnerID=8YFLogxK

U2 - 10.1016/j.jpain.2012.10.009

DO - 10.1016/j.jpain.2012.10.009

M3 - Article

C2 - 23237736

AN - SCOPUS:84873287705

VL - 14

SP - 136

EP - 148

JO - Journal of Pain

JF - Journal of Pain

SN - 1526-5900

IS - 2

ER -